Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  GeNeuro    GNRO   CH0308403085

GENEURO (GNRO)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
01/12/2018 01/15/2018 01/16/2018 01/17/2018 01/18/2018 Date
6.9(c) 6.84(c) 7.04(c) 6.94(c) 6.9(c) Last
4 418 2 968 17 418 6 361 1 562 Volume
+0.58% -0.87% +2.92% -1.42% -0.58% Change
More quotes
Financials (€)
Sales 2017 4,10 M
EBIT 2017 -9,50 M
Net income 2017 -9,28 M
Finance 2017 28,8 M
Yield 2017 -
Sales 2018 19,3 M
EBIT 2018 -3,70 M
Net income 2018 -4,00 M
Finance 2018 15,9 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 18,3x
EV / Sales2018 4,56x
Capitalization 104 M
More Financials
Company
GeNeuro SA engages develops therapeutic products for disorders of the nervous system.It operates in the Research and Development segment for pharmaceutical products.The firm offers GNbAC1, a therapeutic antibody that targets MSRV-Env.It also offers a drug for multiple sclerosis.The company was... 
More about the company
Surperformance© ratings of GeNeuro
Trading Rating : Investor Rating :
More Ratings
Latest news on GENEURO
2017 GENEURO : reports cash and revenue for Q3 2017
2017 GENEURO : Servier and GeNeuro Announce Promising post hoc Analyses of Six Month ..
2017 GENEURO : Servier and Geneuro to present six month results from CHANGE-MS phase ..
2017 GENEURO : Researchers from GeNeuro Describe Findings in Type 1 Diabetes Mellitus..
2017 GENEURO : Retroviral RRMS Treatment GNbAC1 Fails Phase 2 Trial, But Research Con..
2017 GENEURO : Servier and GeNeuro Announce Six-Month Results from CHANGE-MS Phase 2b..
2017 GENEURO : updates on cash, revenue and activities at Q2 2017
2017 GENEURO : Presents Data Supporting Role of Human Endogenous Retroviruses (HERVs)..
2017 GENEURO : Presents Data Supporting Role of Human Endogenous Retroviruses (HERVs)..
2017 GENEURO : initiates Phase 2a study in Australia to treat Type 1 Diabetes
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/10$TSPT GNRO.PA: GeNeuro Enrolls Final Patient in Phase IIa Study of GNbAC1 in .. 
2017$TSPT GNRO.PA: GeNeuro Receives Milestone Payment for Final Patient Visit in .. 
2017GeNeuro : reports cash and revenue for Q3 2017  
2017$TSPT GNRO.PA: GeNeuro Announces 6-Month Data from Phase IIb Study for GNbAC1.. 
2017GeNeuro and Servier Announce Six-Month Results from CHANGE-MS Phase 2b Study ..
1
More tweets
Qtime:90
News from SeekingAlpha
2017 GENEURO SA ORD reports Q3 results
2017 GeNeuro (GNRRF) Presents Review Of Phase llb Week-24 Results - Slideshow
2017 GENEURO SA ORD reports 1H results
2017 GENEURO SA ORD reports Q2 results
2017 GENEURO SA ORD reports Q1 results
Chart GENEURO
Duration : Period :
GeNeuro Technical Analysis Chart | GNRO | CH0308403085 | 4-Traders
Technical analysis trends GENEURO
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 8,30 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Jesús Martin-Garcia Chairman & Chief Executive Officer
Miguel Payro Chief Financial Officer
Giacomo di Nepi Independent Director
Marc Bonneville Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GENEURO21.54%129
CELLTRION, INC.--.--%40 725
IQVIA HOLDINGS INC2.07%20 784
LONZA GROUP2.47%20 682
INCYTE CORPORATION-3.23%19 342
ALNYLAM PHARMACEUTICALS, INC.-1.90%12 256